Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1106-1114

  Svensson, Elin M ^a   Murray, Stephen ^b   Karlsson, Mats O ^a   Dooley, Kelly E ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Global Alliance for TB Drug Development ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug drug interactions; Population pharmacokinetics; Tuberculosis

Indexed keywords

BEDAQUILINE; EFAVIRENZ; RIFAMPICIN; RIFAPENTINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEADY STATE; TUBERCULOSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG INTERACTION; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; YOUNG ADULT;

EID: 84926435138     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku504     Document Type: Article

References (41)

1. WHO. Global Tuberculosis Report 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1.
2. FoxW, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-79.
3. Munro SA, Lewin SA, Smith HJ et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
4. Pablos-Méndez A, Knirsch CA, Barr RG et al. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102: 164-70.
5. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007; issue 4: CD003343.
6. TB Alliance. Our Pipeline. http://www.tballiance.org/pipeline/pipeline.php.
7. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacteriumtuberculosis. Science 2005; 307: 223-7.
8. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
9. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis:long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
10. European Medicines Agency. CHMP Assessment Report: SIRTURO. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002614/WC500158728.pdf.
11. Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-32.
12. Niemi M, Backman JT, Fromm MF et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
13. Burman DWJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-41.
14. Williamson B, Dooley KE, Zhang Y et al. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother 2013; 57: 6366-9.
15. Li AP, Reith MK, Rasmussen A et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 1997; 107: 17-30.
16. Dooley KE, Bliven-Sizemore EE, Weiner M et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012; 91: 881-8.
17. Everitt D, Winter H, Egizi E. Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentin. In: Abstracts of the Nineteenth International AIDS Conference, Washington, DC, 2012. Abstract MOAB0304. http://www.iasociety.org/Abstracts/A200746786.aspx.
18. Winter H, Egizi E,Murray S et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampicin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother, in press.
19. Svensson EM, Aweeka F, Park J-G et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 2013; 57: 2780-7.
20. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
21. Beal S, Sheiner LB, Boeckmann A et al. NONMEM User's Guides (1989-2009). Ellicott City, MD, USA: Icon Development Solutions, 2009.
22. Lindbom L, Pihlgren P, Jonsson EN et al. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79:241-57.
23. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
24. Keizer RJ, van Benten M, Beijnen JH et al. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72-9.
25. Dooley KE, Park J-G, Swindells S et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr 1999 2012; 59: 455-62.
26. van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 2014; 69: 2310-8.
27. Janssen Pharmaceuticals. Sirturo, United States Product Insert. http://www.sirturo.com/sites/default/files/pdf/sirturo-pi.pdf.
28. Acharya C, Hooker AC, Jönsson S et al. A diagnostic tool for population models using non-compartmental analysis: nca_ppc functionality for R. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe, 2014. Abstract 3103. www.page-meeting.org/?abstract=3103.
29. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92.
30. FDA. Center for Drug Evaluation and Research, Application Number:204384Orig1s000, Pharmacology Review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000PharmR.pdf.
31. FDA. Center for Drug Evaluation and Research, Application Number:204384Orig1s000, Clinical Pharmacology and Biopharmaceutics Review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000ClinPharmR.pdf.
32. Mesens N, Steemans M, Hansen E et al. Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol In Vitro 2010; 24:1417-25.
33. Mesens N, Verbeeck J, Rouan M. Elucidating the role of M2 in the preclinical safety profile of TMC207. In: Proceedings of the Thirty-eighth World Conference on Lung Health of the International Union Against Tuberculosis, Cape Town, South Africa, 2007. Abstract PS-71358-11, p. S167. International Union Against Tuberculosis and Lung Disease, Paris, France.
34. Reinach B, de Sousa G, Dostert P et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999; 121: 37-48.
35. Weber A, Kaplan M, Chughtai SA et al. CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. Biopharm Drug Dispos 2001; 22: 157-68.
36. Pinheiro VGF, Ramos LMA, Monteiro HSA et al. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis 2006; 10: 374-9.
37. Zhu M, Namdar R, Stambaugh JJ et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis 2002; 82: 91-6.
38. Peresi E, Silva SMUR, Calvi SA et al. Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. J Bras Pneumol 2008; 34: 942-9.
39. Ramakrishnan K, Shenbagarathai R, Kavitha K et al. Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn J Infect Dis 2008; 61: 202-4.
40. McLeay SC, Vis P, van Heeswijk RPG et al. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 2014; 58: 5315-24.
41. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother 2014; 58: 6406-12.